Press release archive | Oxurion — Advancing Science. Enhancing Vision

EN
NL

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Press release archive

Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)
13 Oct 2021
Positive Phase 2 Part A THR-149 data shared at the America Society of Retina Specialists (ASRS) Annual Scientific Meeting
11 Oct 2021
OXURION to Present at the Lytham Partners Fall 2021 Investor Conference
5 Oct 2021
OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)
30 Sep 2021
Oxurion NV Business & Financial Update – H1 2021
9 Sep 2021
OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress
8 Sep 2021
Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal
17 Aug 2021
Oxurion NV - Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149
16 Aug 2021
OXURION to Participate in Upcoming Investor Meetings
5 Aug 2021
Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149
25 Jun 2021
OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)
10 Jun 2021
OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)
8 Jun 2021
OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
17 May 2021
OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting
30 Apr 2021
OXURION NV to Present at Wet AMD and DME Drug Development Summit
13 Apr 2021
Oxurion NV – Publication in 'Progress in Retinal and Eye Research' highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
7 Apr 2021
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
6 Apr 2021
OXURION to Participate in Upcoming Investor Meetings
31 Mar 2021
Oxurion NV Business and Financial Update – FY 2020
17 Mar 2021
OXURION to Participate in Upcoming Investor Meetings
8 Mar 2021
Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
20 Jan 2021
OXURION to Participate in Upcoming Investor Meetings
7 Jan 2021
OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
9 Nov 2020
Oxurion NV Business Update – Q3 2020
15 Oct 2020
Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
13 Oct 2020
Invitation OXURION R&D Investor Day – Virtual 15 October 2020 at 5.30pm CET/ 11.30am ET
8 Oct 2020
Save the date: Oxurion to host Virtual R&D Investor Day on 15 October 2020
5 Oct 2020
Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4
29 Sep 2020
Oxurion NV Business Update - H1 2020
17 Sep 2020
Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
14 Sep 2020
Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September
11 Sep 2020
Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)
1 Sep 2020
Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer
3 Aug 2020
Oxurion NV Business Update - Q1 2020
7 May 2020
Oxurion NV – COVID-19 Statement
28 Mar 2020
Oxurion NV Business Update – FY 2019
12 Mar 2020
Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference
9 Feb 2020
Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference
5 Feb 2020
Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME
7 Jan 2020